Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
its Q3 2025 results, reporting a smaller-than-anticipated quarterly loss of -$0.61 per share, surpassing consensus projections of -$0.72 by $0.11. Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update The quarter's net loss of $110.6 million was slightly higher than the $111.1 million for the same period a year earlier. Moreover, while general and administrative costs fell to $15.4 million from $19.8 million year-over-year, the company's R&D expenditures rose to $98.9 million from $94.5 million. Immunovant, Inc. (NASDAQ:IMVT) anticipates receiving topline findings in the latter half of 2026 from its proof-of-concept trial in cutaneous lupus erythematosus as well as its IMVT-1402 trial in rheumatoid arthritis. Furthermore, the company expects to release data from its Phase 3 trials of batoclimab for thyroid eye disease in the first half of this year. Following the results, multiple analysts reiterated their views but raised price targets. Among them
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Assessing Immunovant (IMVT) Valuation As Shares Deliver A 25% One Year Return [Yahoo! Finance]Yahoo! Finance
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)PR Newswire
- Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway [Yahoo! Finance]Yahoo! Finance
IMVT
Earnings
- 2/6/26 - Beat
IMVT
Sec Filings
- 2/27/26 - Form 4
- 2/10/26 - Form 144
- 2/6/26 - Form 10-Q
- IMVT's page on the SEC website